down arrow

USANA Health Sciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90328M1071
USD
19.61
-0.6 (-2.97%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

19.5120.15

52 Week

18.4838.85
Valuation
Technical
Day's Volume

CASH

56.25 k

Shareholding (Mar 2025)

FII

4.75%

Held by 83 FIIs

DII

68.55%

Held by 29 DIIs

Promoter

0.18%

How big is USANA Health Sciences, Inc.?

22-Jun-2025

As of Jun 18, USANA Health Sciences, Inc. has a market capitalization of 567.07 million and net sales of 876.24 million with a net profit of 34.81 million over the latest four quarters.

As of Jun 18, USANA Health Sciences, Inc. has a market capitalization of 567.07 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 876.24 million, while the sum of net profit for the same period is 34.81 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 586.33 million and total assets at 748.19 million.

Read More

What does USANA Health Sciences, Inc. do?

22-Jun-2025

USANA Health Sciences, Inc. develops and manufactures nutritional and personal care products, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $250 million and a market cap of $567.07 million.

Overview:<BR>USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products and operates in the Pharmaceuticals & Biotechnology industry within the micro-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 250 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 567.07 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.30 <BR>Return on Equity: 6.57% <BR>Price to Book: 1.07<BR><BR>Contact Details:<BR>Address: 3838 W Parkway Blvd, SALT LAKE CITY UT: 84120-6336 <BR>Tel: 1 801 9547100 <BR>Website: https://www.usana.com/

Read More

Who are in the management team of USANA Health Sciences, Inc.?

22-Jun-2025

As of March 2022, the management team of USANA Health Sciences, Inc. includes Chairman and CEO Kevin Guest, Lead Independent Director Gilbert Fuller, Senior Director Robert Anciaux, Director John Fleming, and Independent Directors Peggie Pelosi and Feng Peng. They oversee the company's strategic direction and operations.

As of March 2022, the management team of USANA Health Sciences, Inc. includes the following individuals:<BR><BR>- Mr. Kevin Guest, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Gilbert Fuller, acting as the Lead Independent Director.<BR>- Mr. Robert Anciaux, who holds the position of Senior Director.<BR>- Mr. John Fleming, serving as a Director.<BR>- Ms. Peggie Pelosi, who is an Independent Director.<BR>- Mr. Feng Peng, also an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is USANA Health Sciences, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, USANA Health Sciences, Inc. has shifted to a bearish trend with weak strength indicators, underperforming the S&P 500 significantly with year-to-date and one-year returns of -17.28% and -23.08%, respectively.

As of 19 September 2025, the technical trend for USANA Health Sciences, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the Bollinger Bands, both showing bearish signals. The weekly MACD is mildly bullish, but this is overshadowed by the overall bearish indicators from the daily timeframe. Additionally, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -17.28% versus the S&P 500's 13.31%, and a one-year return of -23.08% compared to 16.64% for the index.

Read More

Is USANA Health Sciences, Inc. overvalued or undervalued?

05-Nov-2025

As of October 31, 2025, USANA Health Sciences, Inc. is considered very expensive and overvalued with a P/E ratio of 16, poor recent performance (-42.74% year-to-date and -73.15% over five years), especially compared to its peers like Chromadex Corp. and Nature's Sunshine Products, Inc.

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers.<BR><BR>The company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

The company has declared negative results for the last 7 consecutive quarters

  • INTEREST(HY) At USD 0.67 MM has Grown at 550.49%
  • OPERATING CASH FLOW(Y) Lowest at USD 63.01 MM
  • NET PROFIT(HY) At USD 19.06 MM has Grown at -29.34%
2

With ROE of 6.57%, it has a attractive valuation with a 1.03 Price to Book Value

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 565 Million (Micro Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

6.56%

stock-summary
Price to Book

1.06

Revenue and Profits:
Net Sales:
236 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-38.28%
0%
-38.28%
6 Months
-34.06%
0%
-34.06%
1 Year
-49.21%
0%
-49.21%
2 Years
-59.18%
0%
-59.18%
3 Years
-64.12%
0%
-64.12%
4 Years
-80.48%
0%
-80.48%
5 Years
-75.07%
0%
-75.07%

USANA Health Sciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its perceived value. The company appears overvalued based on its current metrics, with a P/E ratio of 16, an EV to EBITDA of 4.61, and a Price to Book Value of 1.03. In comparison, Chromadex Corp. has a P/E of 39.82 and Nature's Sunshine Products, Inc. shows a P/E of 21.11, both indicating that USANA's valuation is not justified relative to its peers. The company's recent performance has been poor, with a year-to-date return of -42.74% compared to the S&P 500's 16.30%, and a staggering -73.15% return over the past five years against the S&P's 109.18%. This stark contrast reinforces the notion that USANA Health Sciences, Inc. is currently overvalued....

Read More

Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating that the stock is overvalued. The company has a P/E ratio of 16, a Price to Book Value of 1.03, and an EV to EBITDA ratio of 4.61. In comparison to peers, Chromadex Corp. has a significantly higher P/E ratio of 39.82, while LifeVantage Corp. presents a more attractive valuation with a P/E of 14.81. Given the current metrics and the valuation grade, USANA Health Sciences appears to be overvalued relative to its peers. Although specific return data is not available, the lack of favorable returns compared to the S&P 500 may reinforce the perception of overvaluation....

Read More

Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for USANA Health Sciences, Inc. moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its P/E ratio of 16, which is lower than the peer average of 16.23 for similar companies such as Chromadex Corp. and Nature's Sunshine Products, Inc., both of which are also categorized as very expensive. Additionally, USANA's EV to EBITDA ratio stands at 4.61, while its peers like LifeVantage Corp. have a more favorable ratio of 8.26, further highlighting its overvaluation. In terms of returns, USANA has significantly underperformed compared to the S&P 500, with a year-to-date decline of 41.07% versus the index's gain of 16.30%. This trend is consistent over longer periods, with a 5-year return of -72.04% compared to the S&P 500's 109.18%. Overall, the combination of valuation metrics and ...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-3.19%
EBIT Growth (5y)
-18.74%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
1.77
Tax Ratio
47.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
61.30%
ROCE (avg)
70.81%
ROE (avg)
18.61%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
1.03
EV to EBIT
6.81
EV to EBITDA
4.61
EV to Capital Employed
1.05
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
15.36%
ROE (Latest)
6.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 53 Schemes (26.47%)

Foreign Institutions

Held by 83 Foreign Institutions (4.75%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -5.49% vs 16.81% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 11.83% vs 106.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "235.80",
          "val2": "249.50",
          "chgp": "-5.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "26.30",
          "val2": "25.90",
          "chgp": "1.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.40",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.40",
          "val2": "9.30",
          "chgp": "11.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "70.90%",
          "val2": "62.80%",
          "chgp": "0.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.22% vs -7.77% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -34.01% vs -7.94% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "854.50",
          "val2": "921.00",
          "chgp": "-7.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "88.60",
          "val2": "113.50",
          "chgp": "-21.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.10",
          "val2": "63.80",
          "chgp": "-34.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "77.60%",
          "val2": "101.10%",
          "chgp": "-2.35%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
235.80
249.50
-5.49%
Operating Profit (PBDIT) excl Other Income
26.30
25.90
1.54%
Interest
0.30
0.40
-25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10.40
9.30
11.83%
Operating Profit Margin (Excl OI)
70.90%
62.80%
0.81%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -5.49% vs 16.81% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 11.83% vs 106.67% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
854.50
921.00
-7.22%
Operating Profit (PBDIT) excl Other Income
88.60
113.50
-21.94%
Interest
0.30
0.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
42.10
63.80
-34.01%
Operating Profit Margin (Excl OI)
77.60%
101.10%
-2.35%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -7.22% vs -7.77% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -34.01% vs -7.94% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About USANA Health Sciences, Inc. stock-summary
stock-summary
USANA Health Sciences, Inc.
Pharmaceuticals & Biotechnology
USANA Health Sciences, Inc. develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia. Its product lines include USANA Nutritionals Essentials, Optimizers, Foods, Sense-beautiful science and All Other. Its USANA Nutritionals Essentials product line includes vitamin and mineral supplements that provide a foundation of total body nutrition for every age group beginning with children of approximately one year. Its Optimizers product line consists of targeted supplements designed to meet individual health and nutritional needs. Its Sense-beautiful science product line includes science-based, personal care products that support skin and hair by providing topical nourishment, moisturization and protection.
Company Coordinates stock-summary
Company Details
3838 W Parkway Blvd , SALT LAKE CITY UT : 84120-6336
stock-summary
Tel: 1 801 9547100
stock-summary
https://www.usana.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."